Skip to main content
VBIO logo

VBIO · Valion Bio, Inc.

Track VBIO — free
$0.12 0.00 (-3.83%)
Market Cap
$2.68M
Shares
22.19M

Valion Bio, Inc. Earnings Call Transcripts

Quarterly earnings calls for Valion Bio, Inc. (VBIO), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Earnings call
FY26 · Q1
2026-05-14
Valion Bio, Inc. (VBIO) Q1 2026 Earnings Call Transcript
Confident tone Velocity Bioworks biomanufacturing / CDMO Intolamid (Entolamod) TLR5 agonist asset Corporate rebranding and governance
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-25
Valion Bio, Inc. (VBIO) Q4 2025 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-14
Valion Bio, Inc. (VBIO) Q3 2025 Earnings Call Transcript
Confident tone Entolimod for acute radiation syndrome (ARS) Strategic transformation to biopharmaceuticals VNS (vagus nerve stimulation) program
Revenue
$146,000
▲ 15.9% YoY
Gross margin
-99.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
Valion Bio, Inc. (VBIO) Q2 2025 Earnings Call Transcript
Confident tone Entolimod for Acute Radiation Syndrome (ARS) Government/defense stockpile opportunity Consumer Health Tech (ClearUP) wind-down
Revenue
$86,000
▼ 38.6% YoY
Diluted EPS
$-2.19
Gross margin
62.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-15
Valion Bio, Inc. (VBIO) Q1 2025 Earnings Call Transcript
Confident tone Entolimod licensing and TLR5 program Government / agency relationships and funding Non-invasive vagus nerve stimulation (VNS) program
Revenue
$70,000
▼ 79% YoY
Diluted EPS
$-2.52
Gross margin
71.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-21
Valion Bio, Inc. (VBIO) Q4 2024 Earnings Call
Revenue
$180,000*
▼ 49.6% YoY
Gross margin
-132.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Valion Bio, Inc. (VBIO) Q3 2024 Earnings Call Transcript
Positive tone Vagus nerve stimulation (VNS) program ClearUP product line turnaround Capital raising strategy
Revenue
$126,000
▼ 55.3% YoY
Diluted EPS
$-3.91
Gross margin
34.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Valion Bio, Inc. (VBIO) Q2 2024 Earnings Call Transcript
Positive tone VNS program / clinical results ClearUP product line Intellectual property and patents
Revenue
$140,000
▼ 13% YoY
Diluted EPS
$-5.37
Gross margin
21.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-25
Valion Bio, Inc. (VBIO) Q4 2023 Earnings Call Transcript
Positive tone Vagus nerve stimulation (VNS) research Gross profit and margin improvement Distribution partnerships
Revenue
$357,000*
▼ 12.3% YoY
Gross margin
1.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-14
Valion Bio, Inc. (VBIO) Q3 2023 Earnings Call Transcript
Revenue
$282,000
▼ 40.9% YoY
Diluted EPS
$-25.16
Gross margin
38.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-14
Valion Bio, Inc. (VBIO) Q2 2023 Earnings Call Transcript
Revenue
$161,000
▼ 69.5% YoY
Diluted EPS
$-121.72
Gross margin
37.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-15
Valion Bio, Inc. (VBIO) Q1 2023 Earnings Call
Revenue
$376,000
▼ 12.1% YoY
Diluted EPS
$-178.84
Gross margin
30.1%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-31
Valion Bio, Inc. (VBIO) Q4 2022 Earnings Call
Revenue
$407,000*
▲ 4.6% YoY
Gross margin
10.1%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Valion Bio, Inc. (VBIO) Q3 2022 Earnings Call
Revenue
$477,000
▲ 72.2% YoY
Diluted EPS
$-459.00
Gross margin
13.2%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-15
Valion Bio, Inc. (VBIO) Q2 2022 Earnings Call
Revenue
$528,000
▲ 97% YoY
Diluted EPS
$-544.00
Gross margin
23.7%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-16
Valion Bio, Inc. (VBIO) Q1 2022 Earnings Call
Revenue
$428,000
▲ 32.5% YoY
Diluted EPS
$-391.00
Gross margin
16.4%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–16 of 16 earnings calls
Key facts CIK 1787740 CUSIP 888705308 13F (30d) 15 filings 12 filers Visit website